Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Long-Term Investments (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Long-Term Investments for 15 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments rose 43.75% year-over-year to $1.1 billion, compared with a TTM value of $1.1 billion through Dec 2025, up 43.75%, and an annual FY2025 reading of $1.1 billion, up 43.75% over the prior year.
  • Long-Term Investments was $1.1 billion for Q4 2025 at Neurocrine Biosciences, up from $998.5 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $1.1 billion in Q4 2025 and bottomed at $244.6 million in Q1 2023.
  • Average Long-Term Investments over 4 years is $620.2 million, with a median of $643.9 million recorded in 2024.
  • The sharpest move saw Long-Term Investments increased 5.81% in 2021, then soared 186.35% in 2024.
  • Year by year, Long-Term Investments stood at $513.7 million in 2021, then skyrocketed by 33.83% to $687.5 million in 2023, then rose by 7.56% to $739.5 million in 2024, then surged by 43.75% to $1.1 billion in 2025.
  • Business Quant data shows Long-Term Investments for NBIX at $1.1 billion in Q4 2025, $998.5 million in Q3 2025, and $873.8 million in Q2 2025.